Compare CBNK & PACB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CBNK | PACB |
|---|---|---|
| Founded | 1974 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Laboratory Analytical Instruments |
| Sector | Finance | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 520.4M | 419.8M |
| IPO Year | 2018 | 2010 |
| Metric | CBNK | PACB |
|---|---|---|
| Price | $31.43 | $1.67 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 2 | 3 |
| Target Price | ★ $35.50 | $1.67 |
| AVG Volume (30 Days) | 58.6K | ★ 5.6M |
| Earning Date | 04-27-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.52% | N/A |
| EPS Growth | ★ 60.85 | N/A |
| EPS | ★ 3.41 | N/A |
| Revenue | N/A | ★ $93,468,000.00 |
| Revenue This Year | $16.20 | $11.32 |
| Revenue Next Year | $8.52 | $12.14 |
| P/E Ratio | $9.19 | ★ N/A |
| Revenue Growth | N/A | ★ 3.04 |
| 52 Week Low | $26.40 | $0.85 |
| 52 Week High | $36.40 | $2.73 |
| Indicator | CBNK | PACB |
|---|---|---|
| Relative Strength Index (RSI) | 52.87 | 59.36 |
| Support Level | $30.18 | $1.68 |
| Resistance Level | $33.46 | $1.79 |
| Average True Range (ATR) | 0.82 | 0.11 |
| MACD | -0.10 | 0.00 |
| Stochastic Oscillator | 45.92 | 72.36 |
Capital Bancorp Inc is a bank holding company. The company through its holdings operates as a commercial-focused community bank that serves businesses, not-for-profit associations, and entrepreneurs throughout the region. The bank operates through four divisions including Commercial Banking, Capital Bank Home Loans, OpenSky, and Windsor Advantage. The company generates majority revenue from the Commercial bank sector. Commercial Banking division focuses on providing personalized service to commercial clients throughout the operations supplemented by lending outside primary market as well as engaging in government guaranteed lending on a national basis.
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Europe Middle East, and Africa and Asia-Pacific.